Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HepA-L
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
HepA-L is a live attenuated hepatitis A vaccine used to prevent infection by the hepatitis A virus (HAV). Unlike inactivated vaccines, HepA-L contains a weakened form of the virus that stimulates an immune response without causing disease. Both inactivated (HepA-I) and live attenuated (HepA-L) hepatitis A vaccines are highly immunogenic and well tolerated, providing long-lasting immunity for at least 20 years post-vaccination. The vaccine is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. It works by inducing the body to produce antibodies against HAV, conferring protection against future exposures[8][10]. Live attenuated HepA vaccines are not available in all countries; for example, they are not licensed in the United States but may be used elsewhere.
- Brand names
- Biovac-A
- Other names
- live attenuated hepatitis A vaccinelive hepatitis A vaccine
Beyond the preview
Go deeper on HepA-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HepA-L.